Obesity-Drugs Focused Stocks Tumble On Wednesday - What's Going On With Eli Lilly, Novo Nordisk, Viking Therapeutics, Structure Therapeutics?
Portfolio Pulse from Vandana Singh
Stocks of Eli Lilly, Novo Nordisk, Viking Therapeutics, and Structure Therapeutics fell on Wednesday following Roche's announcement of promising Phase 1 trial results for its obesity drug CT-996, which showed superior weight loss results compared to existing treatments.

July 17, 2024 | 2:47 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Structure Therapeutics' stock fell 16.01% after Roche's CT-996 trial results showed better weight loss outcomes than Structure's GSBR-1290.
Roche's CT-996 demonstrated superior weight loss results compared to Structure Therapeutics' GSBR-1290, leading to a negative market reaction for GPCR stock.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 100
NEGATIVE IMPACT
Eli Lilly's stock fell 3% after Roche's CT-996 trial results showed better weight loss outcomes than existing treatments, including Eli Lilly's Mounjaro.
Roche's CT-996 demonstrated superior weight loss results compared to Eli Lilly's Mounjaro, leading to a negative market reaction for LLY stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
Novo Nordisk's stock fell 4.15% after Roche's CT-996 trial results showed better weight loss outcomes than Novo Nordisk's Ozempic.
Roche's CT-996 demonstrated superior weight loss results compared to Novo Nordisk's Ozempic, leading to a negative market reaction for NVO stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
Viking Therapeutics' stock fell 11.10% after Roche's CT-996 trial results showed better weight loss outcomes than Viking's VK2735.
Roche's CT-996 demonstrated superior weight loss results compared to Viking Therapeutics' VK2735, leading to a negative market reaction for VKTX stock.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 100